ACT-DMD Trial

Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) lost nearly 8 percent by Monday afternoon. The company released Phase 2 data at the International Congress of the World Muscle Society. Christopher Marai of Oppenheimer maintained an Outperform rating and unchanged $155 price target...